Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib

被引：3
|
作者：
Kelly, Kevin R. [1 ]
Chanan-Khan, Asher [2 ]
Heffner, Leonard T. [3 ]
Somlo, George [4 ]
Siegel, David S. [5 ]
Zimmerman, Todd [6 ]
Karnad, Anand [7 ]
Munshi, Nikhil C. [8 ]
Jagannath, Sundar [9 ]
Greenberg, Allen L. [10 ]
Lonial, Sagar [3 ]
Roy, Vivek [2 ]
Ailawadhi, Sikander [2 ]
Barmaki-Rad, Farima [11 ]
Chavan, Shailesh [12 ]
Patel, Pankaj [12 ]
Wartenberg-Demand, Andrea [11 ]
Haeder, Thomas [11 ]
Anderson, Kenneth C. [13 ]
机构：
[1] Univ So Calif, Los Angeles, CA USA
[2] Mayo Clin, Jacksonville, FL 32224 USA
[3] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[4] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[5] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[6] Univ Chicago Med, Chicago, IL USA
[7] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[8] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA
[9] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA
[10] Mem Canc Inst, Pembroke Pines, FL USA
[11] Biotest AG, Dreieich, Germany
[12] Biotest Pharmaceut Corp, Boca Raton, FL USA
[13] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Treatment of relapsed/refractory multiple myeloma patients with lenalidomide/dexamethasone in routine clinical practice
    Schwarzer, A.
    Fruehauf, S.
    Knigsmann, M.
    Schnell, R.
    Reeb, M.
    Heits, F.
    Tirier, C.
    Prange-Krex, G.
    Knauf, W.
    Bachinger, A.
    Weiligmann, C.
    Hoppe, G.
    Glasmacher, A.
    Schmidt, B.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 291 - 291
  • [42] Our Experience of Using Lenalidomide, Bortezomib and Dexamethasone (RVD) Therapy in Patients with Relapsed/Refractory Multiple Myeloma
    Pogosyan, Gayane
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S340 - S341
  • [43] Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT).
    Vij, Ravi
    Richardson, Paul Gerard Guy
    Jagannath, Sundar
    Siegel, David Samuel DiCapua
    Baz, Rachid C.
    Srinivasan, Shankar
    Larkins, Gail
    Zaki, Mohamed H.
    Hussein, Mohamad A.
    Anderson, Kenneth Carl
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
    P. G. Richardson
    C. C. Hofmeister
    N. S. Raje
    D. S. Siegel
    S. Lonial
    J. Laubach
    Y. A. Efebera
    D. H. Vesole
    A. K. Nooka
    J. Rosenblatt
    D. Doss
    M. H. Zaki
    A. Bensmaine
    J. Herring
    Y. Li
    L. Watkins
    M. S. Chen
    K. C. Anderson
    Leukemia, 2018, 32 : 2305 - 2305
  • [45] Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone
    San-Miguel, Jesus F.
    Dimopoulos, Meletios A.
    Stadtmauer, Edward A.
    Rajkumar, S. Vincent
    Siegel, David
    Bravo, Marie-Laure
    Olesnyckyj, Marta
    Knight, Robert D.
    Zeldis, Jerome B.
    Harousseau, Jean-Luc
    Weber, Donna M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (01): : 38 - 43
  • [46] Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: A phase I study
    Siegel, D. S.
    Weber, D. M.
    Mitsiades, C. S.
    Dimopoulos, M. A.
    Harousseau, J. L.
    Rizvi, S.
    Howe, J.
    Reiser, D.
    Anderson, K. C.
    Richardson, P. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [47] A Phase I Study of Vorinostat in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
    Siegel, David
    Weber, Donna
    Mitsiades, Constantine S.
    Rizvi, Syed
    Garcia-Vargas, Jose
    Howe, Jason
    Reiser, David
    Anderson, Kenneth C.
    Richardson, Paul
    BLOOD, 2008, 112 (11) : 1270 - 1270
  • [48] EFFICACY BY CYTOGENETIC RISK STATUS FOR DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE OR BORTEZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    San-Miguel, J.
    Weisel, K.
    Cook, G.
    Leiba, M.
    Suzuki, K.
    Kumar, S.
    Cavo, M.
    Avet-Loiseau, H.
    Quach, H.
    Hungria, V.
    Lentzsch, S.
    Hajek, R.
    Sonneveld, P.
    Wu, K.
    Qin, X.
    Chiu, C.
    Soong, D.
    Qi, M.
    Schecter, J.
    Dimopoulos, M. A.
    HAEMATOLOGICA, 2017, 102 : 1 - 2
  • [49] Lenalidomide in Combination with Dexamethasone in Elderly Patients with Advanced, Relapsed or Refractory Multiple Myeloma and Renal Failure
    Tosi, Patrizia
    Gamberi, Barbara
    Castagnari, Barbara
    Molinari, Anna Lia
    Savini, Paolo
    Ceccolini, Michela
    Tani, Monica
    Merli, Anna
    Imola, Manuela
    Mianulli, Anna Maria
    Cellini, Claudia
    Tomassetti, Simona
    Merli, Francesco
    Fattori, Pierpaolo
    Zaccaria, Alfonso
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2013, 5 (01): : 1 - 5
  • [50] Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure
    Siegel, David S.
    Schiller, Gary J.
    Song, Kevin W.
    Agajanian, Richy
    Stockerl-Goldstein, Keith
    Kaya, Hakan
    Sebag, Michael
    Samaras, Christy
    Malek, Ehsan
    Talamo, Giampaolo
    Seet, Christopher S.
    Mouro, Jorge
    Pierceall, William E.
    Zafar, Faiza
    Chung, Weiyuan
    Srinivasan, Shankar
    Agarwal, Amit
    Bahlis, Nizar J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (04) : 501 - 510
12345